PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34548471-0	2021	ASXL1 mutations are associated with distinct epigenomic alterations that lead to sensitivity to venetoclax and azacytidine.	Azacitidine	111-122	ASXL transcriptional regulator 1	Homo sapiens	0-5	
34548471-8	2021	In addition, genome-wide methylome analysis of primary MDS samples and isogenic cell lines demonstrated increased gene-body methylation in ASXL1 mutant cells, with consequently increased sensitivity to AZA.	Azacitidine	202-205	ASXL transcriptional regulator 1	Homo sapiens	139-144	
34548471-9	2021	These data mechanistically link the common leukemia-associated mutation ASXL1 to enhanced sensitivity to VEN and AZA via epigenetic upregulation of BCL2 expression and widespread alterations in DNA methylation.	Azacitidine	113-116	ASXL transcriptional regulator 1	Homo sapiens	72-77	
34296432-0	2021	Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations.	Azacitidine	99-110	ASXL transcriptional regulator 1	Homo sapiens	114-119	
34296432-2	2021	We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations.	Azacitidine	114-125	ASXL transcriptional regulator 1	Homo sapiens	135-140	
34296432-2	2021	We studied 153 patients with MDS and del(20q) to assess the incidence, prognostic value and impact on response to azacitidine (AZA) of ASXL1 chromosomal alterations and genetic mutations.	Azacitidine	127-130	ASXL transcriptional regulator 1	Homo sapiens	135-140	
34296432-3	2021	Additionally, in vitro assay of the response to AZA in HAP1 (HAP1WT ) and HAP1 ASXL1 knockout (HAP1KN ) cells was performed.	Azacitidine	48-51	ASXL transcriptional regulator 1	Homo sapiens	79-84